研究疾病:
|
新型冠状病毒肺炎(COVID-19)
|
研究疾病代码:
|
|
Target disease:
|
Novel Coronavirus Pneumonia (COVID-19)
|
Target disease code:
|
研究类型:
Study type:
|
干预性研究
Interventional study
|
研究设计:
Study design:
|
随机平行对照
randomized controlled trial(parallel group design)
|
研究所处阶段:
Study phase:
|
上市后药物
Post-marketing clinical trial
|
研究目的:
|
本研究针对新型冠状病毒肺炎恢复期患者的预后和临床症状改善情况,采用随机、双盲、安慰剂对照、多中心的临床研究方法,对金水宝胶囊干预新冠肺炎恢复期肺功能障碍相关的临床症状进行疗效评价,探讨金水宝胶囊在新冠肺炎患者预后中的有效性与安全性,为中医药干预新冠肺炎恢复期的诊疗提供疗效依据。
|
Objectives of Study:
|
In this study, for the premature and clinical symptoms of patients with COVID - 19 pneumonia recovery periods, the clinical research method of random, double blind, placebo control, multi-center research method is used, and the clinical impairment of Jinshui Capsule is interpretable. The symptoms were evaluated, and the effectiveness and safety of Jinshui Bao Capsule in the prognosis of COVID - 19 pneumonia patients, providing efficacy for the treatment of Chinese medicine intervention in new crown pneumonia recovery period.
|
药物成份或治疗方案详述:
|
|
Description for medicine or protocol of treatment in detail:
|
|
纳入标准:
|
1、符合新型冠状病毒肺炎恢复期诊断标准;
2、气短、多汗、干咳、胸闷、心悸等肺心功能下降的临床不适症状,同时出现其中3个症状者,或单项症状视觉模拟评分法(VAS)≥4分者。
3、治愈出院大于2周的患者;
4、年龄在18~70岁;
5、签署知情同意书。
|
Inclusion criteria
|
1. meet the new coronary virus pneumonia recovery period diagnostic criteria;
2. short breath, sweating, dry cough, chest tightness, palpitations, etc., three symptoms, or single symptom visual simulation score method (VAS) >=4;
3. the cure discharge is more than 2 weeks;
4. aged 18 ~ 70 years old;
5. sign the informed consent.
|
排除标准:
|
1、由于其他原因导致的气短、多汗、干咳、胸闷、心悸等肺心功能下降患者;
2、由于基础疾病等原因,口服药物困难的患者;
3、伴有影响生存的严重基础疾病,包括未被控制的有临床意义的心脏、肺、肾脏、消化、血液病、神经精神疾病、免疫性疾病、代谢性疾病、恶性肿瘤、严重营养不良等;
4、过敏体质,对治疗方案涉及的药物过敏者;
5、妊娠期或哺乳期妇女;
6、精神状态不能合作者,患有精神性疾病、无自制力、不能明确表达者;
7、正参加其它临床试验者;
8、根据研究者判断,会出现入组复杂化或依从性不佳等影响疗效及安全性评估的患者。
|
Exclusion criteria:
|
1. other reasons causted short breath, sweating, dry cough, chest tightness, palpitations and other pulmonary heart function;
2. Patients with difficult drugs due to basic diseases;
3. with severe basic diseases that affect survival, including Uncontrolled has a clinical heart, lung, kidney, digestion, blood disease, neuroplastic disease, immune disease, metabolic disease, malignant tumor, severe malnutrition, etc.;
4. allergic body, drugs involved in treatment Allergies;
5. pregnancy or lactating women;
6. mental state can not be collaborators, suffering from mental illness, no self-control, can not clearly express;
7. are participating in other clinical trials;
8. according to researchers In case of patients affecting efficacy and safety assessment of incoming complications or poor computes.
|
研究实施时间:
Study execute time:
|
从From
2020-04-20
至To
2020-09-30
|
征募观察对象时间:
Recruiting time:
|
从From
2020-04-27
至To
2020-05-15
|